医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GI Dynamics to Provide Shareholder Update on 2017 Second Quarter Results

2017年08月10日 AM07:47
このエントリーをはてなブックマークに追加


 

BOSTON & SYDNEY

GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will update investors on 2017 second quarter results as reported on Form 10Q for the period ended June 30, 2017.

The company will host a webcast at 6 pm EDT 14 August 2017 | 8 am AEST 15 August 2017.

Accessing the Webcast:

The webcast may be accessed by clicking here or on the GI Dynamics website. The link provided will give you access to view and listen to the webcast on a computer, tablet or mobile device.

For those preferring to listen by telephone, please dial-in five minutes prior to the start of the call. Regional dial-in numbers are as follows:

United States (Toll-Free):

        877 407 6184

United Kingdom (Toll-Free):

0 800 756 3429

Germany (Toll-Free):

0 800 182 0040

Australia (Toll-Free):

1 800 687 004

International (Toll; charges will apply):

201 389 0877

The transcript for the call will be available on the company’s website shortly following the webcast.

About GI Dynamics

GI Dynamics, Inc. (ASX:GID) is the developer of EndoBarrier, the first endoscopically delivered device approved for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit www.gidynamics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170809006235/en/

CONTACT

GI Dynamics, Inc.
Investor Relations
United States:
Janell
Shields, +1 781-357-3280
investor@gidynamics.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 十年磨一剑,Biosafe Defenses LLC宣布新突破性消毒剂
  • バイオセーフ・ディフェンシズ が10年にわたる研究を経て画期的な新消毒剤を発表
  • 第6届世界患者安全暨科技年度峰会将在英国伦敦召开
  • Avita Medical and BARDA Execute a US$24.3m Contract Option
  • CDISC and Cohen Veterans Bioscience Announce Public Review for Post Traumatic Stress Disorder Therapeutic Area User Guide